Lilly Announces Detailed Results of the Phase 3 Solanezumab EXPEDITION Studies Following a Presentation of the Independent Analyses by the Alzheimer's Disease Cooperative Study (ADCS)
- Lilly's analysis, as previously reported, showed primary endpoints, both cognitive and functional, were not met in the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer's disease
- In Lilly's pre-specified secondary analysis of pooled data in patients with mild Alzheimer's disease, a statistically significant slowing of cognitive decline was shown; this finding represented a 34 percent reduction in decline
- Independent analyses of EXPEDITION studies conducted by the ADCS were generally similar to Lilly's top-line results reported on August 24, 2012
- Next steps for solanezumab will be determined after discussions with regulators